ENTA presents preclinical data for NASH compound, EDP-305 at AASLD; there are five poster presentations: http://finance.yahoo.com/news/enanta-announces-data-fxr-agonist-130100913.html EDP-305 is wholly owned by ENTA. Please see #msg-125454754 for related info.